![]() | A major contributor to this article appears to have a close connection with its subject.(February 2017) |
The Side-Out Foundation, located in Fairfax, Virginia, is an American non-profit breast cancer charity that raises awareness and funds for the treatment of metastatic breast cancer. Side-Out fundraises mainly through volleyball-related events. Their mission, as it is stated on their website is, "to unite volleyball players and coaches and to have them work toward the common goal of furthering breast cancer awareness, education, and patient services." [1] Side-Out has a board of directors and team of scientific advisers. [2]
![]() The Side-Out Foundation's Logo | |
Founded | 2004 |
---|---|
Type | Nonprofit Organization |
Headquarters | 3935 University Dr. Fairfax, VA 22030 |
Website | side-out.org |
The Side-Out Foundation was established in 2004 by West Springfield High School girls volleyball coach Rick Dunetz, after his mother, Gloria Dunetz, was diagnosed with stage IV breast cancer. [3]
The Dig Pink movement was started by The-Side Out Foundation. On August 13, 2014, The Side-Out Story, a documentary about the Side-Out Foundation was published to Rick Dunetz's YouTube channel. [4] The film also was shown at the All Sports Los Angeles Film Festival where it received an Audience Choice Award. [5]
Side-Out's activities raise about $1.5 million for the organization each year. [3] Since their roots are in the sport of volleyball their events and activities revolve around the sport.
Each year hundreds of Middle School, High School, and College volleyball teams host Dig Pink events as part of the rally to raise both funds and awareness for metastatic breast cancer. [3] The 2013 Dig Pink Rally raised $1.3 million from 925 teams across the country. [6]
The main beneficiary of the Side-Out Foundation is their own clinical trial, the Side-Out Protocol. [7] [8] The Side-Out Protocol focuses on the treatment of metastatic breast cancer using applied proteomics and molecular medicine. [9] [10] The main basis of The Side-Out Protocol is using personalized medicine as treatment for metastatic breast cancer and is one of the first uses of proteomics in treating breast cancer. [3]
Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Breast Cancer Awareness Month (BCAM), also referred to in the United States as National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer charities every October to increase awareness of the disease and to raise funds for research into its cause, prevention, diagnosis, treatment and cure.
Triple-negative breast cancer (TNBC) is any breast cancer that lacks or show low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and amplification. Triple-negative is sometimes used as a surrogate term for basal-like.
The Breast Cancer Research Foundation (BCRF) is an independent, not-for-profit organization which has raised $569.4 million to support clinical and translational research on breast cancer at medical institutions in the United States and abroad. BCRF currently funds over 275 researchers in 15 countries.
The Prostate Cancer Foundation (PCF), headquartered in Santa Monica, California, funds research into the prevention and cure of prostate cancer.
ICanServe Foundation, Inc., formerly Information on Breast Cancer and Other Services, is a non-stock, non-profit organization that advocates early breast cancer detection through breast self-examination. Based in Manila, Philippines, and co-founded in 1999 by journalist Kara Magsanoc-Alikpala, a breast cancer survivor, the advocacy group empowers women with breast cancer and women cancer-related information so they can have a voice in their own health care. Its mission is to arm women with breast care health and breast cancer information so they can make informed decisions about their health. It also provides access to special services that will help the breast cancer survivor recover and heal more effectively.
Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1.
High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
Buparlisib is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. Buparlisib was under investigation as a treatment for advanced breast cancer but was abandoned due to negative results. It is still under investigation as a potential treatment for head and neck squamous cell carcinoma (HNSCC).
Alpelisib, sold under the brand name Piqray, is a medication sold by Novartis and used to treat certain types of breast cancer. It is used together with fulvestrant. It is taken by mouth.it is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Project Pink Blue, registered as Health & Psychological Trust Centre is a cancer nonprofit engaged in raising cancer awareness, patient navigation, advocacy and free breast and cervical cancer screening for women living in poverty. The organization launched Nigeria's first patient navigation in 2015 and a toll- free telephone centre 08000CANCER in 2016 Project PINK BLUE won the SPARC Metastatic Breast Cancer challenge grant by Union for International Cancer Control and Pfizer Oncology in Lisbon, Portugal.
Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.
Bisantrene, trademarked as Zantrene, is an anthracenyl bishydrazone with anthracycline-like antineoplastic activity. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in activity, but unlike anthracyclines like doxorubicin, exhibits little cardiotoxicity.
{{cite web}}
: Missing or empty |title=
(help)